A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Condition: Biliary Tract Cancer Interventions: Drug: Nivolumab; Drug: DKN-01 Sponsors: Massachusetts General Hospital; Bristol-Myers Squibb; Leap Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials